TNF Polymorphisms Independently Predict Outcome in Patients with B-Cell Non-Hodgkin’s Lymphoma

AUTHORS

NF Osman 1 , TL Holyoake 1 , A Zeineldin 2 , Amal A Elkordy 3 , * , IG McQuaker 1

1 Section of Experimental Haematology and Department of Clinical and Laboratory Haematology, Royal Infirmary, Glasgow, United Kingdom

2 Menoufia University Hospitals, Shebin El-kom, Egypt

3 Department of Pharmacy, Health and Well-being, University of Sunderland, Sunderland, United Kingdom

How to Cite: Osman N, Holyoake T, Zeineldin A, Elkordy A A, McQuaker I. TNF Polymorphisms Independently Predict Outcome in Patients with B-Cell Non-Hodgkin’s Lymphoma , Int J Cancer Manag. 2009 ; 2(1):e80500.

ARTICLE INFORMATION

International Journal of Cancer Management: 2 (1); e80500
Published Online: March 30, 2009
Article Type: Research Article
Received: March 30, 2009
Accepted: March 30, 2009

Crossmark

CHEKING

READ FULL TEXT
Abstract

Objectives: Tumour Necrosis Factor α (TNFα) and Lymphotoxin α (LTα) have been implicated in the pathogenesis of lymphoproliferative disorders. Patients with B-cell non-Hodgkin’s lymphoma (NHL) often have high serum levels of TNF which may be associated with a poor outcome. TNFα and LTα polymorphisms are known to influence expression of these cytokines and may explain the variable response to therapy.

Patients and Methods: In patients with NHL, serum levels of TNFα and LTα were measured. DNA was typed using allele specific PCR and restriction fragment length polymorphism for the –308 TNFα and +252 LTα polymorphisms and comparison was made with clinical outcome.

Results: The presence of high producing alleles was significantly associated with high serum levels of TNFα and LTα. The presence of 2 or more high producing alleles was significantly associated with more advanced disease at presentation (stage III and IV), p=0.024, a higher International Prognostic Index (IPI) score, p=0.038, failure to achieve a complete remission (CR) after 1st line therapy (88% vs 33%, p=0.01) and shorter progression free survival (PFS) (median 24 months compared with 78 months, p=0.001). Multivariate analysis confirmed that TNF highrisk haplotype (HRH) was an independent prognostic factor for PFS.

Conclusions: These results demonstrate that TNF polymorphisms are independent prognostic factors in NHL. Further study is required to further define the importance of TNF polymorphisms within different lymphoma subtypes and with different therapeutic approaches.

Keywords

B-cell Non-Hodgkin’s lymphoma survival TNF polymorphisms

© 2009, Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.

Fulltext

The Full text is available in PDF.

COMMENTS

LEAVE A COMMENT HERE: